View Older Stories View More Recent Stories

Oct 6, 2017 04:00AM Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing

Oct 3, 2017 12:17PM Form SC 13G/A Mirati Therapeutics, Filed by: venBio Select Advisor LLC

Sep 18, 2017 09:00AM Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology

Aug 16, 2017 04:00PM Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline

Aug 14, 2017 12:31PM Form 13F-HR venBio Select Advisor For: Jun 30

Aug 10, 2017 09:01AM Apellis Pharmaceuticals Announces $60 Million Series E Financing

Jul 18, 2017 08:00AM Menlo Therapeutics Raises $50M

Jul 6, 2017 06:08AM Form SC 13G Aurinia Pharmaceuticals Filed by: venBio Global Strategic Fund, L.P.

Jul 5, 2017 05:57PM venBio Global Strategic Fund, L.P. Announces Update to Stake in Aurinia Pharmaceuticals Inc.

Jun 15, 2017 04:44PM Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating Officer

Jun 8, 2017 05:00PM Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

May 24, 2017 12:54PM Schulte Roth & Zabel Hosts Seminar: Shareholder Activism in the UK

May 15, 2017 12:20PM Form 13F-HR venBio Select Advisor For: Mar 31

May 9, 2017 11:33AM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

May 8, 2017 05:11PM Form SC 13G Verona Pharma plc Filed by: venBio Global Strategic Fund II L.P.

May 5, 2017 08:49AM Immunomedics (IMMU) Announces $125M Private Placement of Convertible Preferred Stock; Outlines Strategic Steps to Drive Stockholder Value; CEO to Step Down

May 5, 2017 08:46AM Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value

Mar 17, 2017 05:16PM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Mar 3, 2017 12:00PM Stockholders Endorse venBio’s Case for Meaningful Change at Immunomedics

Mar 3, 2017 10:19AM Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders

Mar 2, 2017 05:01PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Mar 2, 2017 01:52PM venBio Encourages Stockholders to Vote for Change at Immunomedics (IMMU)

Mar 2, 2017 01:51PM venBio Encourages Stockholders to Vote for Change

Mar 2, 2017 10:24AM Immunomedics (IMMU) Says Revised Settlement Offer Rejected By venBio

Mar 2, 2017 10:23AM Immunomedics Outlines Revised Settlement Offer Rejected By venBio; Announces Actions That Are In The Best Interests Of All Stockholders

Mar 2, 2017 06:02AM Form D/A venBio Global Strategic

Feb 27, 2017 08:00AM Immunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation

Feb 22, 2017 05:05PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Feb 22, 2017 08:32AM venBio Sends Letter to Immunomedics Stockholders

Feb 21, 2017 08:00AM Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws

Feb 15, 2017 05:26PM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Feb 15, 2017 04:15PM Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders

Feb 14, 2017 04:47PM Immunomedics Comments on Baseless venBio Lawsuit

Feb 14, 2017 04:02PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Feb 14, 2017 12:27PM Form 13F-HR venBio Select Advisor For: Dec 31

Feb 14, 2017 11:52AM venBio Takes Steps to Protect Immunomedics (IMMU) Stockholders Following Its Partnership with Seattle Genetics (SGEN)

Feb 14, 2017 11:50AM venBio Takes Steps to Protect Rights of Immunomedics Stockholders

Feb 13, 2017 03:28PM Form SC 13G/A Nabriva Therapeutics AG Filed by: venBio Global Strategic Fund II L.P.

Feb 10, 2017 05:16PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Feb 10, 2017 04:14PM venBio Comments on Immunomedics Partnership Announcement

Feb 9, 2017 05:00PM Form SC 13G AGENUS INC Filed by: venBio Select Advisor LLC

Feb 9, 2017 04:43PM Form SC 13G/A Lion Biotechnologies, Filed by: venBio Select Advisor LLC

Feb 9, 2017 04:41PM Form SC 13G/A Mirati Therapeutics, Filed by: venBio Select Advisor LLC

Feb 9, 2017 04:36PM Form SC 13G ALIMERA SCIENCES INC Filed by: venBio Select Advisor LLC

Feb 9, 2017 04:33PM Form SC 13G Oncobiologics, Inc. Filed by: venBio Select Advisor LLC

Feb 9, 2017 04:00PM Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments

Feb 7, 2017 05:01PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

Feb 7, 2017 12:45PM Immunomedics Strongly Encourages Stockholders to Reject the venBio Nominees — With Four New Independent Directors and a Robust Value-Maximization Process, Stockholders Should Not Risk Giving venBio

Feb 7, 2017 09:00AM Glass Lewis Endorses Full Slate of venBio Nominees at Immunomedics

Feb 6, 2017 05:02PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC

View More Recent Stories View Older Stories